Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 1,101–1,200 of 15,747
Marasco, V., Carniti, C., Guidetti, A., Farina, L., Magni, M., Miceli, R., Calabretta, L., Verderio, P., Ljevar, S., Serpenti, F., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17877 · Cited by 99
“The phase 3 trials of mRNA-1273 (Moderna) and BNT162b2 (Pfizer BioNTech), the first mRNA-based vaccines, which target the spike protein to elicit protective immunity, demonstrated an efficacy at preventing COVID-19 in healthy individuals of 94% and 95%, respectively.(4,5) Seroconversion occurred in almost all vaccinat…”
BackgroundKim, M., Lee, Y. W., Kim, S. R., Kim, J., Min, T. K., Park, H., Shin, M., Ye, Y., Lee, S., Lee, J., et al. (2021) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2021.13.4.526 · Cited by 102
“AAAAI9 Consider skin test May mask initial symptoms, however, fexofenadine or cetirizine can be considered in individuals with mild symptoms (pruritis or urticaria only) No description in the positional paper (5); allergist supervised graded vaccine challenge can be considered, however, the safety and efficacy of this…”
BackgroundThe Pivotal Role of Chemical Modifications in mRNA Therapeutics
Liu, A., & Wang, X. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.901510 · Cited by 117
“Indeed, both vaccines were able to be produced within 10months after the sequencing of the SARS-CoV-2 genome and proved to be over 90% effective (Polack et al., 2020; El Sahly et al., 2021).”
BackgroundTao, K., Tzou, P. L., Nouhin, J., Bonilla, H. F., Jagannathan, P., & Shafer, R. W. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00109-21 · Cited by 111
Seyahi, E., Bakhdiyarli, G., Öztaş, M., Kuşkucu, M. A., Tok, Y., Süt, N., Ozcifci, G., Özçağlayan, A., Balkan, İ. İ., Saltoğlu, N., et al. (2021) · Rheumatology International · doi:10.1007/s00296-021-04910-7 · Cited by 94
Covid-19: Pfizer vaccine efficacy was 52% after first dose and 95% after second dose, paper shows
Mahase, E. (2020) · BMJ · doi:10.1136/bmj.m4826 · Cited by 100
Optimizing 5’UTRs for mRNA-delivered gene editing using deep learning
Castillo-Hair, S., Fedak, S., Wang, B., Linder, J., Havens, K., Certo, M., & Seelig, G. (2024) · Nature Communications · doi:10.1038/s41467-024-49508-2 · Cited by 98
Nucleic Acid Vaccines for COVID-19: A Paradigm Shift in the Vaccine Development Arena
Chavda, V. P., Hossain, M. M. M., Beladiya, J., & Apostolopoulos, V. (2021) · Biologics · doi:10.3390/biologics1030020 · Cited by 100
Gehrau, V., Fujarski, S., Lorenz, H., Schieb, C., & Blöbaum, B. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18094678 · Cited by 93
“By the time of the survey, more than 200 vaccines had been developed, yet only few were proven to be efficient and safe for use [2,3].”
BackgroundShavit, R., Segal, R. M., Kidon, M. I., Offengenden, I., Yahia, S. H., Machnes‐Maayan, D., Lifshitz, Y., Niznik, S., Frizinsky, S., Deutch, M., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.22255 · Cited by 94
Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China
Zhang, M., Zhang, T.-T., Shi, G., Cheng, F., Zheng, Y.-M., Tung, T., & Chen, H. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1925112 · Cited by 98
Population immunity predicts evolutionary trajectories of SARS-CoV-2
Meijers, M., Ruchnewitz, D., Eberhardt, J., Łuksza, M., & Lässig, M. (2023) · Cell · doi:10.1016/j.cell.2023.09.022 · Cited by 110
Lipid nanoparticle-based mRNA delivery systems for cancer immunotherapy
Han, J., Lim, J., Wang, C. J., Han, J., Shin, H. E., Kim, S.-N., Jeong, D., Lee, S. H., Chun, B.-H., Park, C. G., et al. (2023) · Nano Convergence · doi:10.1186/s40580-023-00385-3 · Cited by 106
SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization
Hoffmann, M., Zhang, L., Krüger, N., Graichen, L., Kleine-Weber, H., Hofmann-Winkler, H., Kempf, A., Nessler, S., Riggert, J., Winkler, M. S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109017 · Cited by 90
Khan, N. H., & Mahmud, N. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.05.044 · Cited by 96
“At present, 2 vaccines are in wide clinical use in the US, the BNT162b2 messenger RNA coronavirus disease 2019 (COVID-19) vaccine from Pfizer and the messenger RNA-1273 SARS-CoV-2 vaccine from Moderna.(10,11) Both vaccines have been shown to have greater than 90% efficacy, and to date, more than 100 million vaccines h…”
InfluentialAmodio, D., Ruggiero, A., Sgrulletti, M., Pighi, C., Cotugno, N., Medri, C., Rocchi, F., Colagrossi, L., Russo, C., Zaffina, S., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.727850 · Cited by 107
Viral Vectors for COVID-19 Vaccine Development
Lundstrom, K. H. (2021) · Viruses · doi:10.3390/v13020317 · Cited by 108
Application of Bayesian approaches in drug development: starting a virtuous cycle
Ruberg, S. J., Beckers, F., Hemmings, R., Honig, P. K., Irony, T., LaVange, L. M., Liebérman, G., Mayne, J. T., & Moscicki, R. A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00638-0 · Cited by 112
“There were more than 43,000 patients randomized and 36,523 evaluable for efficacy at the time the first results were published 9 .”
BackgroundMethodInfluentialChung, Y.-S., Lam, C.-Y., Tan, P.-H., Tsang, H. F., & Wong, S. C. C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158155 · Cited by 141
ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines
Hoffmann, M. A. G., Yang, Z., Huey‐Tubman, K. E., Cohen, A. A., Gnanapragasam, P. N. P., Nakatomi, L. M., Storm, K. N., Moon, W. J., Lin, P. J. C., West, A. P., et al. (2023) · Cell · doi:10.1016/j.cell.2023.04.024 · Cited by 107
Watanabe, A., Kani, R., Iwagami, M., Takagi, H., Yasuhara, J., & Kuno, T. (2023) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2022.6243 · Cited by 106
Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine
Huang, X., Zhang, G., Tang, T., Gao, X., & Liang, T. (2022) · Military Medical Research · doi:10.1186/s40779-022-00416-w · Cited by 121
Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course
Muri, J., Cecchinato, V., Cavalli, A., Shanbhag, A. A., Matkovic, M., Biggiogero, M., Maida, P. A., Moritz, J., Toscano, C., Ghovehoud, E., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01445-w · Cited by 104
“4f) and who received two doses of mRNA-based COVID-19 vaccine 37,38 , enrolled on the day of first vaccine dose or earlier, between November 2020 and June 2021 (ECCT: CE-3428).”
Lazarus, R., Baos, S., Cappel-Porter, H., et al. (2021) · Repository@Nottingham (University of Nottingham) · doi:10.1016/s0140-6736%2821%2902329-1 · Cited by 92
B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity
Lapuente, D., Winkler, T., & Tenbusch, M. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01095-w · Cited by 111
Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials
Sobhani, N., Scaggiante, B., Morris, R. M., Chai, D., Catalano, M., Tardiel-Cyril, D. R., Neeli, P. K., Roviello, G., Mondani, G., & Li, Y. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102429 · Cited by 107
“This factor is beneficial for making mRNA available as an off-the-shelf cancer vaccine and for personalized neoantigen vaccination [12].”
Influential(2021) · doi:10.1101/2021.05.04.442663 · Cited by 259
Pagano, L., Salmanton‐García, J., Marchesi, F., Blennow, O., da Silva, M. G., Glenthøj, A. B., van Doesum, J. A., Bilgin, Y. M., López‐García, A., Itri, F., et al. (2022) · Blood · doi:10.1182/blood.2022017257 · Cited by 97
Adverse Events After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease
Botwin, G. J., Li, D., Figueiredo, J. C., Cheng, S. C., Braun, J. G., McGovern, D. P. B., & Melmed, G. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001342 · Cited by 88
“We analyzed postvaccination symptoms by age, sex, IBD classification, vaccine type, and medication classes using Student t test (R version 3.5.1).”
InfluentialAntibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity
Delmonte, O. M., Bergerson, J., Burbelo, P. D., Durkee-Shock, J. R., Dobbs, K., Bosticardo, M., Keller, M. D., McDermott, D. H., Rao, V. K., Dimitrova, D., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.08.016 · Cited by 96
Intention to Receive the COVID-19 Vaccine Booster Dose in a University Community in Italy
Folcarelli, L., del Giudice, G. M., Corea, F., & Angelillo, I. F. (2022) · Vaccines · doi:10.3390/vaccines10020146 · Cited by 101
“Moreover, the availability of vaccines that are effective in preventing symptomatic and asymptomatic SARS-CoV-2 infection has raised hopes of reducing the spread of SARS-CoV-2 infection [3].”
The coronavirus disease 2019 vaccine in pregnancy: risks, benefits, and recommendations
Stafford, I. A., Parchem, J. G., & Sibai, B. M. (2021) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2021.01.022 · Cited by 89
Britton, A., Fleming-Dutra, K. E., Shang, N., Smith, Z., Dorji, T., Derado, G., Accorsi, E. K., Ajani, U. A., Miller, J., Schrag, S. J., et al. (2022) · JAMA · doi:10.1001/jama.2022.2068 · Cited by 84
Nanotechnology-Based Strategies to Overcome Current Barriers in Gene Delivery
Mirón-Barroso, S., Domènech, E. B., & Trigueros, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168537 · Cited by 91
“After the recent success of SARS-CoV-2 vaccines, lipid nanoparticles have become widely known vectors for delivering genetic material [48,49].”
BackgroundAllergy to COVID-19 vaccines: A current update
Cabanillas, B., & Novak, N. (2021) · Allergology International · doi:10.1016/j.alit.2021.04.003 · Cited by 99
The success of SARS-CoV-2 vaccines and challenges ahead
Subbarao, K. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.016 · Cited by 101
Buhre, J. S., Pongrácz, T., Künsting, I., Lixenfeld, A. S., Wang, W., Nouta, J., Lehrian, S., Schmelter, F., Lunding, H. B., Dühring, L., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1020844 · Cited by 103
“The regimens for six vaccination cohorts varied as follows: (i) 48 naïve individuals received two doses of the BioNTech/Pfizer vaccine BNT162b2 (each 30 μg) (3); (ii) 25 naïve individuals received two doses of”
MethodCOVID-19 Vaccine Acceptance among College Students: A Theory-Based Analysis
Sharma, M., Davis, R. E., & Wilkerson, A. H. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18094617 · Cited by 92
Engineered ACE2 decoy mitigates lung injury and death induced by SARS-CoV-2 variants
Zhang, L., Dutta, S., Xiong, S., Chan, M. C., Chan, K. K., Fan, T. M., Bailey, K. L., Lindeblad, M. O., Cooper, L. M., Rong, L., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-021-00965-6 · Cited by 89
Hakroush, S., & Tampe, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.762006 · Cited by 99
“Common adverse events include mild to moderate reactions at the injection site, fever, fatigue, body aches, and headache (2).”
BackgroundHong, J., Xu, X., Yang, J., Zheng, J., Dai, S.-M., Zhou, J., Zhang, Q., Ruan, Y., & Ling, C. (2021) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2021.10.004 · Cited by 86
Pagano, L., Salmanton‐García, J., Marchesi, F., López‐García, A., Lamure, S., Itri, F., da Silva, M. G., Dragonetti, G., Falces‐Romero, I., van Doesum, J. A., et al. (2021) · Blood · doi:10.1182/blood.2021014124 · Cited by 89
The impact of SARS-CoV-2 vaccination on Alpha and Delta variant transmissionPreprint
Eyre, D., Taylor, D., Purver, M., Chapman, D., Fowler, T., Pouwels, K., Walker, A., & Peto, T. (2021) · medRxiv · doi:10.1101/2021.09.28.21264260 · Cited by 105
COVID-19 vaccines: Considering sex differences in efficacy and safety
Jensen, A., Strømme, M., Moyassari, S., Chadha, A. S., Tartaglia, M. C., Szoeke, C. E. I., & Ferretti, M. T. (2022) · Contemporary Clinical Trials · doi:10.1016/j.cct.2022.106700 · Cited by 96
Edmonds, C. E., Zuckerman, S. P., & Conant, E. F. (2021) · American Journal of Roentgenology · doi:10.2214/ajr.21.25604 · Cited by 90
Oyibo, S. O. (2021) · Cureus · doi:10.7759/cureus.16045 · Cited by 90
“The common side effects of these vaccines, such as pain in the injected site, allergic skin reactions, flu-like symptoms, headache, fatigue and fever, have been well documented [9,10].”
BackgroundHồ, N. T., Hughes, S. G., Ta, V. T., Lan, P. T., Đỗ, Q., Nguyễn, T. V., Phạm, A. T. V., Đặng, M. T. N., Nguyễn, L. V., Trịnh, Q. V., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47905-1 · Cited by 103
Praet, J. T. V., Reynders, M., Bacquer, D. D., Viaene, L., Schoutteten, M., Caluwé, R., Doubel, P., Heylen, L., Bel, A. V. D., Vlem, B. V., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021070908 · Cited by 98
SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?
Chakraborty, S., Mallajosyula, V. V. A., Tato, C. M., Tan, G. S., & Wang, T. T. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.014 · Cited by 99
COVID-19 vaccines adverse events: potential molecular mechanisms
Lamprinou, M., Sachinidis, A., Stamoula, Ε., Vavilis, T., & Papazisis, G. (2023) · Immunologic Research · doi:10.1007/s12026-023-09357-5 · Cited by 96
Muena, N. A., García‐Salum, T., Pardo‐Roa, C., Avendaño, M. J., Serrano, E. F., Lévican, J., Almonacid, L. I., Valenzuela, G. H., Poblete, E., Strohmeier, S., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103972 · Cited by 91
Influenza Neuraminidase Characteristics and Potential as a Vaccine Target
Creytens, S., Pascha, M. N., Ballegeer, M., Saelens, X., & de Haan, C. A. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.786617 · Cited by 96
Current approaches to HIV vaccine development: a narrative review
Kim, J., Vasan, S., Kim, J. H., & Ake, J. A. (2021) · Journal of the International AIDS Society · doi:10.1002/jia2.25793 · Cited by 108
“The ChAdOx1 vector is a component of the Astra Zeneca COVID-19 vaccine, which has been granted a conditional marketing authorization or emergency use in over 50 countries [74,75].”
BackgroundAntibody response to mRNA SARS-CoV-2 vaccine among dialysis patients—a prospective cohort study
Agur, T., Ben-Dor, N., Goldman, S. N., Lichtenberg, S., Herman‐Edelstein, M., Yahav, D., Rozen‐Zvi, B., & Zingerman, B. V. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab155 · Cited by 87
Bakrania, A. K., Joshi, N., Zhao, X., Zheng, G., & Bhat, M. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106706 · Cited by 108
Maruggi, G., Mallett, C. P., Westerbeck, J. W., Chen, T., Lofano, G., Friedrich, K., Qu, L., Sun, J. T., McAuliffe, J., Kanitkar, A., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.001 · Cited by 88
501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro
Liu, H., Wei, P., Zhang, Q., Chen, Z., Aviszus, K., Downing, W., Peterson, S. W., Reynoso, L., Downey, G. P., Frankel, S. K., et al. (2021) · mAbs · doi:10.1080/19420862.2021.1919285 · Cited by 97
Chen, G.-L., Li, X.-F., Dai, X.-H., Li, N., Cheng, M.-L., Huang, Z., Shen, J., Ge, Y.-H., Shen, Z.-W., Deng, Y.-Q., et al. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00280-9 · Cited by 89
Sex as an important factor in nanomedicine
Hajipour, M. J., Aghaverdi, H., Serpooshan, V., Vali, H., Sheibani, S., & Mahmoudi, M. (2021) · Nature Communications · doi:10.1038/s41467-021-23230-9 · Cited by 96
Lipid nanoparticles allow efficient and harmless ex vivo gene editing of human hematopoietic cells
Vavassori, V., Ferrari, S., Beretta, S., Asperti, C., Albano, L., Annoni, A., Gaddoni, C., Varesi, A., Soldi, M., Cuomo, A., et al. (2023) · Blood · doi:10.1182/blood.2022019333 · Cited by 97
Naranbhai, V., Pernat, C. A., Gavralidis, A., Denis, K. S., Lam, E. C., Spring, L. M., Isakoff, S. J., Farmer, J. R., Zubiri, L., Hobbs, G. S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01891 · Cited by 93
Roghani, A. (2021) · JMIRx Med · doi:10.2196/29324 · Cited by 89
A flexible, thermostable nanostructured lipid carrier platform for RNA vaccine delivery
Gerhardt, A., Voigt, E., Archer, M., Reed, S., Larson, E., Van Hoeven, N., Kramer, R., Fox, C., & Casper, C. (2022) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2022.03.009 · Cited by 89
“The Emergency Use Authorization granted to two safe and highly effective mRNA vaccines targeting SARS-CoV-2, less than 1 year after sequencing the novel coronavirus, highlights the power of this new technology.(5,6) However, one of the biggest challenges facing these extraordinary new vaccines is the ability to succes…”
Evolution, Mode of Transmission, and Mutational Landscape of Newly Emerging SARS-CoV-2 Variants
Chakraborty, C., Sharma, A. R., Bhattacharya, M., Agoramoorthy, G., & Lee, S. (2021) · mBio · doi:10.1128/mbio.01140-21 · Cited by 88
Babalola, O. E., Bode, C. O., Ajayi, A. A., Alakaloko, F. M., Akase, I. E., Otrofanowei, E., Salu, O. B., Adeyemo, W. L., Ademuyiwa, A. O., & Omilabu, S. (2022) · QJM: An International Journal of Medicine · doi:10.1093/qjmed/hcab035 · Cited by 89
A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability
Voigt, E. A., Gerhardt, A., Hanson, D., Jennewein, M. F., Battisti, P., Reed, S., Singh, J., Mohamath, R., Bakken, J., Beaver, S., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00549-y · Cited by 89
Dalvie, N. C., Rodriguez‐Aponte, S. A., Hartwell, B. L., Tostanoski, L. H., Biedermann, A. M., Crowell, L. E., Kaur, K., Kumru, O. S., Carter, L. P., Yu, J., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2106845118 · Cited by 91
Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses
Nathan, A., Rossin, E. J., Kaseke, C., Park, R. J., Khatri, A., Koundakjian, D., Urbach, J. M., Singh, N. K., Bashirova, A., Tano-Menka, R., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.029 · Cited by 87
Response to mRNA vaccination for COVID-19 among patients with multiple myeloma
Stampfer, S. D., Goldwater, M., Jew, S. K., Bujarski, S. E., Regidor, B. S. S., Daniely, D., Chen, H., Xu, N., Li, M., Green, T., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01354-7 · Cited by 92
Omo‐Lamai, S., Wang, Y., Patel, M. N., Milosavljevic, A., Zuschlag, D. W., Poddar, S., Wu, J., Wang, L., Dong, F., Espy, C. L., et al. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-01974-5 · Cited by 202
“In addition to efficient delivery of RNA, the other reason for the widespread use of LNPs is their safety record, which is well illustrated by the COVID-19 vaccines 4,5 .”
Kanokudom, S., Assawakosri, S., Suntronwong, N., Auphimai, C., Nilyanimit, P., Vichaiwattana, P., Thongmee, T., Yorsaeng, R., Srimuan, D., Thatsanatorn, T., et al. (2022) · Vaccines · doi:10.3390/vaccines10010086 · Cited by 91
Vaccine protection against the SARS-CoV-2 Omicron variant in macaques
Chandrashekar, A., Yu, J., McMahan, K., Jacob-Dolan, C., Liu, J., He, X., Hope, D. L., Anioke, T., Barrett, J., Chung, B., et al. (2022) · Cell · doi:10.1016/j.cell.2022.03.024 · Cited by 87
US public investment in development of mRNA covid-19 vaccines: retrospective cohort study
Lalani, H. S., Nagar, S., Sarpatwari, A., Barenie, R. E., Avorn, J., Rome, B. N., & Kesselheim, A. S. (2023) · BMJ · doi:10.1136/bmj-2022-073747 · Cited by 131
Branching Ionizable Lipids Can Enhance the Stability, Fusogenicity, and Functional Delivery of mRNA
Hashiba, K., Sato, Y., Taguchi, M., Sakamoto, S., Otsu, A., Maeda, Y., Shishido, T., Murakawa, M., Arimichi, O., & Harashima, H. (2022) · Small Science · doi:10.1002/smsc.202200071 · Cited by 113
Peptide-Based Nanoparticles for Therapeutic Nucleic Acid Delivery
Boisguérin, P., Konate, K., Josse, E., Vivès, É., & Deshayes, S. (2021) · Biomedicines · doi:10.3390/biomedicines9050583 · Cited by 95
“More recently, resulting from the worldwide COVID-19 pandemic, two vaccines based on mRNA technology were put on the market by the companies Pfizer/BioNTec [3] and Moderna [4].”
BackgroundThe Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines
Chan, R. W. Y., Liu, S., Cheung, J. Y., Tsun, J. G., Chan, K. C. C., Chan, K. Y. Y., Fung, G. P. G., Li, A. M., & Lam, H. S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.744887 · Cited by 93
Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients
Carr, E. J., Wu, M., Harvey, R., Wall, E. C., Kelly, G. P., Hussain, S., Howell, M. T., Kassiotis, G., Swanton, C., Gandhi, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01854-7 · Cited by 93
Therapeutic Potential of Metformin in COVID-19: Reasoning for Its Protective Role
Samuel, S. M., Varghese, E., & Büsselberg, D. (2021) · Trends in Microbiology · doi:10.1016/j.tim.2021.03.004 · Cited by 92
(2021) · doi:10.21203/rs.3.rs-228079/v1 · Cited by 840
Li, X., Qi, J., Wang, J., Hu, W., Zhou, W., Wang, Y., & Li, T. (2024) · Theranostics · doi:10.7150/thno.84291 · Cited by 111
“In a phase III trial with over 43,000 participants, the vaccine demonstrated a remarkable 95% overall efficacy in preventing COVID-19 infection and was also effective in a mass vaccination campaign [132, 133].”
BackgroundCerebral Venous Thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine
Dias, L., Soares-dos-Reis, R., Meira, J., Ferrão, D., Ribeirinho-Soares, P., Pastor, A., Gama, G., Fonseca, L., Fagundes, V., & Carvalho, M. (2021) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2021.105906 · Cited by 93
SARS-CoV-2 Vaccine Induced Atypical Immune Responses in Antibody Defects: Everybody Does their Best
Salinas, A. F., Mortari, E. P., Terreri, S., Quintarelli, C., Pulvirenti, F., Cecca, S. D., Guercio, M., Milito, C., Bonanni, L., Auria, S., et al. (2021) · Journal of Clinical Immunology · doi:10.1007/s10875-021-01133-0 · Cited by 92
Synthetic Messenger RNA-Based Vaccines: From Scorn to Hype
Pascolo, S. (2021) · Viruses · doi:10.3390/v13020270 · Cited by 87
A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual screening
Gorgulla, C., Padmanabha Das, K. M., Leigh, K. E., Cespugli, M., Fischer, P. D., Wang, Z.-F., Tesseyre, G., Pandita, S., Shnapir, A., Calderaio, A., et al. (2021) · iScience · doi:10.1016/j.isci.2020.102021 · Cited by 93
John, R., monpara, J., Swaminathan, S., & Kalhapure, R. S. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16010131 · Cited by 107
“The mRNA-1273 vaccine, like the BNT162b2 vaccine, showed an incidence rate of adverse effects at around 12.6 cases per million doses (second dose) that were less severe and fatal, requiring no medical intervention [160,165,166].”
InfluentialTeh, J. S. K., Coussement, J., Neoh, Z. C. F., Spelman, T. D., Lazarakis, S., Slavin, M. A., & Teh, B. W. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021006333 · Cited by 94
Yang, Z., Han, Y., Ding, S., Shi, W., Zhou, T., Finzi, A., Kwong, P. D., Mothes, W., & Lu, M. (2022) · mBio · doi:10.1128/mbio.03227-21 · Cited by 79
Efficacy and Safety of COVID-19 Vaccines in Phase III Trials: A Meta-Analysis
Cheng, H., Peng, Z., Luo, W., Si, S., Mo, M., Zhou, H., Xin, X., Liu, H., & Yu, Y. (2021) · Vaccines · doi:10.3390/vaccines9060582 · Cited by 91
“…2020 to 22 June 2020 Healthy adults 18 to 55 years of age or 65 to 85 years of age USA 18–55 years: 36.1 (19–54); 65–85 years: 69.1 (65–77) 18–55 years: 38.1; 65–85 years: 47.6 Polack et al., 2020 NCT04368728 Phase III, multicenter, randomized, observed-blind, placebo-controlled BioNTech/ Fosun…”
InfluentialHuang, Q., Zeng, J., & Yan, J. (2021) · Journal of Genetics and Genomics · doi:10.1016/j.jgg.2021.02.006 · Cited by 87
Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination
Yu, A., & Tu, M. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107967 · Cited by 95
Soroudi, S., Jaafari, M. R., & Arabi, L. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.06.023 · Cited by 102
Current State of the First COVID-19 Vaccines
Prüβ, B. M. (2021) · Vaccines · doi:10.3390/vaccines9010030 · Cited by 99
Townsend, J. P., Hassler, H. B., Sah, P., Galvani, A. P., & Dornburg, A. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2204336119 · Cited by 96
Fei, Y., Yu, X., Liu, P., Ren, H., Wei, T., & Cheng, Q. (2024) · Advanced Materials · doi:10.1002/adma.202409812 · Cited by 104
Autoimmune phenomena following SARS-CoV-2 vaccination
Ishay, Y., Kenig, A., Tsemach-Toren, T., Amer, R., Rubin, L., Hershkovitz, Y., & Kharouf, F. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107970 · Cited by 91
“This tremendous vaccination rate provides an opportunity to detect rare adverse events not reported in the original trial [3].”
Vaccines for COVID-19: Where do we stand in 2021?
Sharma, K., Koirala, A., Nicolopoulos, K., Chiu, C., Wood, N., & Britton, P. N. (2021) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2021.07.001 · Cited by 103
“6) [35] Symptomatic illness: Adults 65 years: effectiveness 96 4% (95 9– 97 0) [37]”
Wilhelm, A., Toptan, T., Pallas, C., Wolf, T., Goetsch, U., Gottschalk, R., Vehreschild, M. J. G. T., Ciesek, S., & Widera, M. (2021) · Viruses · doi:10.3390/v13091693 · Cited by 85
“In combination with cellular responses vaccination protects against severe COVID-19 disease [4,5].”
BackgroundGao, F., Mallajosyula, V. V. A., Arunachalam, P. S., van der Ploeg, K., Manohar, M., Röltgen, K., Yang, F., Wirz, O. F., Hoh, R. A., Haraguchi, E., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.03.005 · Cited by 101
“The COVID-19 pandemic has resulted in the rapid development of several novel vaccine platforms, including the mRNA-based Pfizer/BioNTech BNT162b2 vaccine.(1,2) The mRNA vaccine formulations show high levels of protection and stimulate robust innate and adaptive immune responses.”
BackgroundIntranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection
Vaca, G. B., Meyer, M., Cadete, A., Hsiao, C. J., Golding, A. S., Jeon, A. B., Jacquinet, E., Azcue, E., Guan, C. M., Sanchez-Felix, X., et al. (2023) · Science Advances · doi:10.1126/sciadv.adh1655 · Cited by 109
COVID ‐19 and the peripheral nervous system. A 2‐year review from the pandemic to the vaccine era
Taga, A., & Lauria, G. (2022) · Journal of the Peripheral Nervous System · doi:10.1111/jns.12482 · Cited by 97
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.